Multiple Effects Cost-Effectiveness Analysis in Cost-Disutility Space
暂无分享,去创建一个
[1] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[2] Bas Groot Koerkamp,et al. Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] F. Roila,et al. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. López‐Soriano,et al. Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Optimal Management of Cancer Anorexia–cachexia Syndrome , 2022 .
[5] Simon Eckermann,et al. The Value of Value of Information , 2012, PharmacoEconomics.
[6] A. Abernethy,et al. Preference for place of care and place of death in palliative care: are these different questions? , 2008, Palliative medicine.
[7] T. Coelli,et al. Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice. , 2013, Social science & medicine.
[8] K. Arrow,et al. Uncertainty and the Evaluation of Public Investment Decisions , 2014 .
[9] D. Currow,et al. Preliminary Development and Validation of a New End-of-Life Patient-Reported Outcome Measure Assessing the Ability of Patients to Finalise Their Affairs at the End of Life , 2014, PloS one.
[10] Andrew Briggs,et al. Value based pricing for NHS drugs: an opportunity not to be missed? , 2008, BMJ : British Medical Journal.
[11] Simon Eckermann,et al. Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies , 2011, PharmacoEconomics.
[12] Hans Keiding,et al. Cost-effectiveness with multiple outcomes. , 2004, Health economics.
[13] S D Walter,et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.
[14] S. Dy,et al. Evidence-Based Approaches to Other Symptoms in Advanced Cancer , 2010, Cancer journal.
[15] Miguel A Negrín,et al. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. , 2006, Health economics.
[16] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[17] P. Novotny,et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A H Briggs,et al. Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.
[19] D. Currow,et al. What are the essential medications in pallative care? - a survey of Australian palliative care doctors. , 2006, Australian family physician.
[20] A. Inui. Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management , 2002, CA: a cancer journal for clinicians.
[21] J. Zivin. Cost-effectiveness analysis with risk aversion. , 2001, Health economics.
[22] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[23] Karl Claxton,et al. Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[24] J. Richardson,et al. Maximizing health benefits vs egalitarianism: an Australian survey of health issues. , 1995, Social science & medicine.
[25] S. Eckermann. Hospital Performance Including Quality: Creating Economic Incentives Consistent with Evidence-Based Medicine , 2004 .
[26] Andrew R Willan,et al. Indirect comparison: relative risk fallacies and odds solution. , 2009, Journal of clinical epidemiology.
[27] D. Currow,et al. Better Informing Decision Making with Multiple Outcomes Cost-Effectiveness Analysis under Uncertainty in Cost-Disutility Space , 2015, PloS one.
[28] N. Zethraeus,et al. Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.
[29] Paula Ravasco,et al. Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.
[30] J. Richardson,et al. Treatment costs and priority setting in health care: A qualitative study , 2009, Australia and New Zealand health policy.
[31] L. Hanson,et al. Research priorities for geriatric palliative care: goals, values, and preferences. , 2013, Journal of palliative medicine.
[32] Andrew Briggs,et al. Health Technology Assessment in the Cost-Disutility Plane , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.